Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • CCC Cancer Update
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Frontiers in neurology. 2021 Sep 8. doi: 10.3389/fneur.2021.697467. pmc: PMC8455825
    Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry.
    Nabbout R1,  Belousova E2,  Benedik MP3,  Carter T4,  Cottin V5,  Curatolo P6,  Dahlin M7,  D'Amato L8,  Beaure d'Augères G9,  de Vries PJ10,  Ferreira JC11,  Feucht M12,  Fladrowski C13,  Hertzberg C14,  Jozwiak S15,  Lawson JA16,  Macaya A17,  Marques R18,  O'Callaghan F19,  Qin J20,  Sauter M21,  Shah S22,  Takahashi Y23,  Touraine R24,  Youroukos S25,  Zonnenberg B26,  Jansen AC27,  Kingswood JC28
    Author information
    1Department of Pediatric Neurology, Reference Centre for Rare Epilepsies, Member of EPICARE Network, Necker Enfants Malades Hospital, Université de Paris, Institut Imagine (Inserm U1163), Paris, France.
    2Department of Pediatrics, Research and Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russia.
    3Department of Pediatric Neurology, SPS Paediatric Clinic, Ljubljana, Slovenia.
    4Tuberous Sclerosis Association, Nottingham, United Kingdom.
    5Department of Respiratory Medicine, Hôpital Louis Pradel, Claude Bernard University Lyon 1, Lyon, France.
    6Department of Neurology, Tor Vergata University Hospital, Rome, Italy.
    7Neuropediatric Unit, Karolinska University Hospital, Stockholm, Sweden.
    8Novartis Farma S.p.A., Origgio, Italy.
    9Tuberous Sclerosis Association of Bourneville, Gradignan, France.
    10Division of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa.
    11Neurologia Pediátrica, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
    12Department of Pediatrics and Adolescent Medicine, Medical University of Vienna (Affiliated Partner of the ERN EpiCARE), Vienna, Austria.
    13Tuberous Sclerosis Association ONLUS, Milan, Italy.
    14Zentrum für Sozialpädiatrie und Neuropädiatrie (DBZ), Vivantes Hospital Neukoelln, Berlin, Germany.
    15Department of Child Neurology, Medical University of Warsaw, Warsaw, Poland.
    16Department of Neurology, The Tuberous Sclerosis Multidisciplinary Management Clinic, Sydney Children's Hospital, Randwick, NSW, Australia.
    17Department of Pediatric Neurology, Vall d'Hebron University Hospital, Barcelona, Spain.
    18Novartis Farma S.p.A., Origgio, Italy.
    19Paediatric Neuroscience, Institute of Child Health, University College London, London, United Kingdom.
    20Department of Pediatrics, Peking University People's Hospital, Beijing, China.
    21Klinkverbund Allgäu gGmbH Hospital, Kempten, Germany.
    22Novartis Healthcare Pvt. Ltd., Hyderabad, India.
    23National Epilepsy Center, National Hospital Organization (NHO), Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.
    24Department of Genetics, Centre Hospitalier Universitaire (CHU)-Hôpital Nord, Saint Etienne, France.
    25First Department of Paediatrics, Athens University Medical School, St. Sophia Children's Hospital, Athens, Greece.
    26Department of Internal Medicine, University Medical Center, Utrecht, Netherlands.
    27Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel Vrije Universiteit Brussel (VUB), Brussels, Belgium.
    28Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Centre, St Georges University of London, London, United Kingdom.
    Abstract

    Epilepsy is the most common neurological manifestation in individuals with tuberous sclerosis complex (TSC). However, real-world evidence on diagnosis and treatment patterns is limited. Here, we present data from TuberOus Sclerosis registry to increase disease Awareness (TOSCA) on changes in patterns of epilepsy diagnosis, treatments, and outcomes over time, and detailed epilepsy characteristics from the epilepsy substudy. TuberOus Sclerosis registry to increase disease Awareness (TOSCA) was a multicentre, international disease registry, consisting of a main study that collected data on overall diagnostic characteristics and associated clinical features, and six substudies focusing on specific TSC manifestations. The epilepsy substudy investigated detailed epilepsy characteristics and their correlation to genotype and intelligence quotient (IQ). Epilepsy was reported in 85% of participants, more commonly in younger individuals (67.8% in 1970s to 91.8% in last decade), while rate of treatments was similar across ages (>93% for both infantile spasms and focal seizures, except prior to 1960). Vigabatrin (VGB) was the most commonly used antiepileptic drugs (AEDs). Individuals with infantile spasms showed a higher treatment response over time with lower usage of steroids. Individuals with focal seizures reported similar rates of drug resistance (32.5-43.3%). Use of vagus nerve stimulation (VNS), ketogenic diet, and surgery remained low. The epilepsy substudy included 162 individuals from nine countries. At epilepsy onset, most individuals with infantile spasms (73.2%) and focal seizures (74.5%) received monotherapies. Vigabatrin was first-line treatment in 45% of individuals with infantile spasms. Changes in initial AEDs were commonly reported due to inadequate efficacy. TSC1 mutations were associated with less severe epilepsy phenotypes and more individuals with normal IQ. In individuals with TSC diagnosis before seizure onset, electroencephalogram (EEG) was performed prior to seizures in only 12.5 and 25% of subsequent infantile spasms and focal seizures, respectively. Our study confirms the high prevalence of epilepsy in TSC individuals and less severe phenotypes with mutations. Vigabatrin improved the outcome of infantile spasms and should be used as first-line treatment. There is, however, still a need for improving therapies in focal seizures. Electroencephalogram follow-up prior to seizure-onset should be promoted for all infants with TSC in order to facilitate preventive or early treatment.


    Copyright © 2021 Nabbout, Belousova, Benedik, Carter, Cottin, Curatolo, Dahlin, D'Amato, Beaure d'Augères, de Vries, Ferreira, Feucht, Fladrowski, Hertzberg, Jozwiak, Lawson, Macaya, Marques, O'Callaghan, Qin, Sauter, Shah, Takahashi, Touraine, Youroukos, Zonnenberg, Jansen and Kingswood.

    KEYWORDS: TOSCA, TSC, epilepsy, registry, tuberous sclerosis complex

    Publikations ID: 34566842
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt